papillary thyroid cancer glp-1 Overscreening of patients on glucagon-like peptide-1 receptor agonists: A second “epidemic” of overdiagnosis? Endocrine Research Exclusive Bundle:A.1 Bottle｜Starter Pack GLP-1 Risks Older Adults

papillary thyroid cancer glp-1 Overscreening of patients on glucagon-like peptide-1 receptor agonists: A second “epidemic” of overdiagnosis? Endocrine Research Exclusive Bundle:A.1 Bottle｜Starter Pack GLP-1 Risks Older Adults

GLP-1 Risks Older Adults Should Consider

How does the PlexusDx Precision Peptide Genetic Test help with medication choices

Endocrine Research

Exclusive Bundle:A.1 Bottle｜Starter Pack

Importantly, the pivotal cardiovascular and obesity outcome trials of GLP-1RAs, including the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN), Semaglutide Treatment Effect in People with obesity (STEP), and SURPASS (tirzepatide) programs, did not report clinically meaningful increases in AITD or sustained thyroid dysfunction [7,8,30]